Eli Lilly and Company (NYSE:LLY) Stake Increased by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund raised its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 102,264 shares of the company’s stock after buying an additional 1,100 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Eli Lilly and were worth $8,416,000 as of its most recent filing with the SEC.

A number of other institutional investors have also bought and sold shares of LLY. Sunbelt Securities Inc. increased its stake in shares of Eli Lilly and by 0.5% in the first quarter. Sunbelt Securities Inc. now owns 3,721 shares of the company’s stock worth $313,000 after buying an additional 17 shares during the period. Northwest Quadrant Wealth Management LLC increased its stake in shares of Eli Lilly and by 0.5% in the first quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock worth $290,000 after buying an additional 19 shares during the period. Pillar Pacific Capital Management LLC increased its stake in shares of Eli Lilly and by 0.3% in the first quarter. Pillar Pacific Capital Management LLC now owns 7,077 shares of the company’s stock worth $595,000 after buying an additional 20 shares during the period. Guardian Life Insurance Co. of America increased its stake in shares of Eli Lilly and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 3,747 shares of the company’s stock worth $315,000 after buying an additional 25 shares during the period. Finally, Jackson Grant Investment Advisers Inc. increased its stake in shares of Eli Lilly and by 0.8% in the fourth quarter. Jackson Grant Investment Advisers Inc. now owns 3,961 shares of the company’s stock worth $291,000 after buying an additional 30 shares during the period. Hedge funds and other institutional investors own 75.59% of the company’s stock.

Shares of Eli Lilly and Company (NYSE LLY) opened at 81.49 on Tuesday. The company has a 50 day moving average of $82.84 and a 200-day moving average of $81.87. The company has a market cap of $85.97 billion, a price-to-earnings ratio of 35.26 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72.

Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The company had revenue of $5.82 billion during the quarter, compared to analysts’ expectations of $5.60 billion. During the same period in the prior year, the business earned $0.86 earnings per share. Eli Lilly and’s revenue for the quarter was up 7.8% compared to the same quarter last year. On average, equities research analysts expect that Eli Lilly and Company will post $4.16 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th will be given a $0.52 dividend. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 annualized dividend and a dividend yield of 2.55%. Eli Lilly and’s dividend payout ratio is 90.04%.

ILLEGAL ACTIVITY NOTICE: “[[title]]” was originally reported by [[site]] and is the sole property of of [[site]]. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at [[permalink]].

LLY has been the subject of a number of recent research reports. Goldman Sachs Group, Inc. (The) reiterated a “buy” rating and set a $92.00 price target on shares of Eli Lilly and in a report on Tuesday, May 16th. BMO Capital Markets set a $71.00 price target on shares of Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday, April 25th. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Tuesday, April 18th. Credit Suisse Group restated an “outperform” rating and issued a $87.00 target price on shares of Eli Lilly and in a report on Wednesday, April 19th. Finally, Argus downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating and boosted their target price for the company from $64.18 to $81.00 in a report on Thursday, April 27th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $88.27.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now directly owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Melissa S. Barnes sold 1,900 shares of the firm’s stock in a transaction on Monday, June 12th. The stock was sold at an average price of $80.78, for a total value of $153,482.00. Following the completion of the transaction, the insider now directly owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The disclosure for this sale can be found here. Insiders sold 669,733 shares of company stock valued at $55,845,287 over the last three months. 0.20% of the stock is owned by company insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.